It has been documented that treatment with SFN generates significant reduction of HDAC activity in lysate cells of HCT116 colon cancer, cancer cells of prostate, breast and human peripheral blood mononuclear cells [31]. This evidence concerns the gene HDAC9 and malignant colon neoplasm.